Compile Data Set for Download or QSAR
Report error Found 41 Enz. Inhib. hit(s) with all data for entry = 12520
TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707478(US20240409542, Example 36)
Affinity DataEC50:  71nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707472(US20240409542, Example 30)
Affinity DataEC50:  83nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707457(US20240409542, Example 15)
Affinity DataEC50:  99nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707458(US20240409542, Example 16)
Affinity DataEC50:  129nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707443(US20240409542, Example 1)
Affinity DataEC50:  180nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707442(US20240409542, Example TEPP-46)
Affinity DataEC50:  185nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707442(US20240409542, Example TEPP-46)
Affinity DataEC50:  185nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707466(US20240409542, Example 24)
Affinity DataEC50:  188nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707479(US20240409542, Example 37)
Affinity DataEC50:  207nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707481(US20240409542, Example 39)
Affinity DataEC50:  217nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707462(US20240409542, Example 20)
Affinity DataEC50:  272nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707471(US20240409542, Example 29)
Affinity DataEC50:  280nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707445(US20240409542, Example 3)
Affinity DataEC50:  303nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707444(US20240409542, Example 2)
Affinity DataEC50:  306nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707465(US20240409542, Example 23)
Affinity DataEC50:  313nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707448(US20240409542, Example 6)
Affinity DataEC50:  317nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707467(US20240409542, Example 25)
Affinity DataEC50:  342nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707449(US20240409542, Example 7)
Affinity DataEC50:  346nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707475(US20240409542, Example 33)
Affinity DataEC50:  354nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707474(US20240409542, Example 32)
Affinity DataEC50:  365nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707468(US20240409542, Example 26)
Affinity DataEC50:  372nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707464(US20240409542, Example 22)
Affinity DataEC50:  385nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707470(US20240409542, Example 28)
Affinity DataEC50:  385nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707460(US20240409542, Example 18)
Affinity DataEC50:  394nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707473(US20240409542, Example 31)
Affinity DataEC50:  423nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707476(US20240409542, Example 34)
Affinity DataEC50:  440nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707456(US20240409542, Example 14)
Affinity DataEC50:  512nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707477(US20240409542, Example 35)
Affinity DataEC50:  569nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707447(US20240409542, Example 5)
Affinity DataEC50:  591nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707455(US20240409542, Example 13)
Affinity DataEC50:  702nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707480(US20240409542, Example 38)
Affinity DataEC50:  759nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707453(US20240409542, Example 11)
Affinity DataEC50:  846nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707461(US20240409542, Example 19)
Affinity DataEC50:  869nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707459(US20240409542, Example 17)
Affinity DataEC50:  901nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707469(US20240409542, Example 27)
Affinity DataEC50:  919nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707463(US20240409542, Example 21)
Affinity DataEC50:  986nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707446(US20240409542, Example 4)
Affinity DataEC50:  1.14E+3nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707454(US20240409542, Example 12)
Affinity DataEC50:  1.49E+3nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707450(US20240409542, Example 8)
Affinity DataEC50:  1.74E+3nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707451(US20240409542, Example 9)
Affinity DataEC50:  1.77E+3nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent

TargetPyruvate kinase PKM(Human)
Sitryx Therapeutics

US Patent
LigandPNGBDBM707452(US20240409542, Example 10)
Affinity DataEC50:  4.68E+3nMAssay Description:Human PKM2 was diluted into Assay Buffer comprising 50 mM imidazole, 50 mM KCl, 7 mM MgCl2, 0.01% Tween20, 0.05% BSA (pH 7.2) to a final concentratio...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
4/23/2025
Entry Details
US Patent